Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Lymphoma, Non-Hodgkin 2Carcinoma, Basal Cell 2Basal Cell Nevus Syndrome 2Upper Tract Urothelial Carcinomas 1Solid Tumors 1Serous Ovarian Cancer 1Recurrence 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Ovarian Neoplasms 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Amyloidosis 1

Interventions

Paclitaxel 12atezolizumab 11Gemcitabine 9pembrolizumab 8Injections 6Carboplatin 6Irinotecan 5Docetaxel 5Cetuximab 5tocilizumab 4navitoclax 4Leucovorin 4Fluorouracil 4Bevacizumab 4olaparib 3cobimetinib 3Oxaliplatin 3Nivolumab 3zolbetuximab 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2tivozanib 2tislelizumab 2spartalizumab 2ridaforolimus 2plocabulin 2obinutuzumab 2motesanib diphosphate 2liposomal doxorubicin 2linifanib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumors × Drug Evaluation × Clear all
NCT04972422 2021-09-05

A Phase 1b Study of ZN-c3 in Chinese Subjects

Zentera Therapeutics HK Limited

Phase 1 Unknown
38 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡